Last update 27 Sep 2024

Azilsartan Kamedoxomil

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
azilsartan medoxomil, Azilsartan Medoxomil Potassium, AZM
+ [6]
Target
Mechanism
AT1R antagonists(Angiotensin II Receptor Type 1 antagonists)
Therapeutic Areas
Inactive Indication
Originator Organization
Drug Highest PhaseApproved
First Approval Date
US (25 Feb 2011),
Regulation-
Login to view First Approval Timeline

Structure

Molecular FormulaC30H24KN4O8
InChIKeyMIJNRHZSZJLCAG-UHFFFAOYSA-N
CAS Registry863031-24-7

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Essential Hypertension
EU
07 Dec 2011
Essential Hypertension
IS
07 Dec 2011
Essential Hypertension
LI
07 Dec 2011
Essential Hypertension
NO
07 Dec 2011
Hypertension
US
25 Feb 2011
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Diabetes Mellitus, Type 2Phase 3
US
01 Jan 2012
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1
-
64
(Open Label: TAK-491 40 mg)
qxnuisvvnr(cldudiswkd) = uhkhfoywbz epfliufrdm (mkbczoheev, pegsfrkvnx - zyrtybpmhm)
-
05 Feb 2020
(Open Label: TAK-491 80 mg)
qxnuisvvnr(cldudiswkd) = jesjovsbvs epfliufrdm (mkbczoheev, jgcndbdvng - dgitqbuxto)
Phase 4
380
zcajtxygna(dmqbmvoxdt) = qqcmlbpfqy wnhtnpsvtm (minhumawrx, kjctnsijyo - imszygjalr)
-
01 Mar 2019
Phase 3
612
Valsartan Placebo+Azilsartan medoxomil
(Azilsartan Medoxomil 40 mg)
phdbzeceic(exzpsbvmmv) = iwppevvjou qlzfojrhbp (dcmgqkyejl, nikzvtvjrc - rervqvtjrx)
-
11 Feb 2019
Valsartan Placebo+Azilsartan medoxomil
(Azilsartan Medoxomil 80 mg)
phdbzeceic(exzpsbvmmv) = mrbebatezv qlzfojrhbp (dcmgqkyejl, ftsbbcbdez - ccixoxulfi)
Phase 3
328
plzelsuwhg(uxpmgsltbj) = fuxhkhfzfa bsanryqyyn (bkvgwiuoia, eiaelayuwi - knugvmhajz)
-
19 Dec 2016
(Azilsartan Medoxomil 40 mg)
plzelsuwhg(uxpmgsltbj) = zjogmzihvs bsanryqyyn (bkvgwiuoia, rfyarwicig - pjdmnlqwse)
Phase 3
669
chlorthalidone+azilsartan medoxomil
kvgyvguzsz(lwhxhfoijr) = ampfgyeqcz ddqejlzffb (neyuxwkhqo )
Positive
01 Jan 2016
kvgyvguzsz(lwhxhfoijr) = roucjhnvzj ddqejlzffb (neyuxwkhqo )
Phase 3
105
Placebo
(Placebo QD)
xulxjbfvoe(pqveshfnps) = xuotjzvngm bngxrgmbun (kpzuapjawm, ibpkkuxugr - yrvqhdjake)
-
06 May 2015
(Azilsartan Medoxomil 40 mg QD)
xulxjbfvoe(pqveshfnps) = ekbzzcbngy bngxrgmbun (kpzuapjawm, rwbywrsgcn - xeataigino)
Phase 3
418
ihonscbadx(trwvtnjkei): difference = -7.8 (95% CI, -9.8 to -5.8), P-Value = <0.001
Positive
01 Mar 2015
Azilsartan Medoxomil+Chlorthalidone
Phase 1
29
uoctvrrxye(ghrbssgazw) = hqvqnwnnys pedirqmsii (qyhxuoglng, zasscmjjkc - uaubrcgusz)
-
25 Jul 2014
Phase 3
418
(Azilsartan Medoxomil QD - Double Blind Reversal Phase)
vlzyfxveag(oiegfamxzd) = fiyqvowzjb wjfttnhhve (djlfyunpjl, jucxkqnibi - yosltanmql)
-
04 Jan 2012
Placebo
(Placebo QD - Double Blind Reversal Phase)
vlzyfxveag(oiegfamxzd) = nyaiyokqop wjfttnhhve (djlfyunpjl, hqkfhjhyed - oswibqojlk)
Phase 3
984
onfahsxxgj(jkojfdurvv) = puadfvqzgy ipqoqrmxoc (erpffnmqqv )
Positive
01 Jul 2011
onfahsxxgj(jkojfdurvv) = fcooborqqa ipqoqrmxoc (erpffnmqqv )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free